Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Idiopathic Pulmonary Fibrosis | Review

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management

Authors: Eslam E. Abd El-Fattah, Amr Y. Zakaria

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Liver fibrosis is a liver disease in which there is an excessive buildup of extracellular matrix proteins, including collagen. By regulating cytokine production and the inflammatory response, heat shock proteins (HSPs) contribute significantly to a wider spectrum of fibrotic illnesses, such as lung, liver, and idiopathic pulmonary fibrosis by aiding in the folding and assembly of freshly synthesized proteins, HSPs serve as chaperones. HSP70 is one of the key HSPs in avoiding protein aggregation which induces its action by sending unfolded and/or misfolded proteins to the ubiquitin–proteasome degradation pathway and antagonizing influence on epithelial-mesenchymal transition. HSP47, on the other hand, is crucial for boosting collagen synthesis, and deposition, and fostering the emergence of fibrotic disorders. The current review aims to provide light on how HSP70 and HSP47 affect hepatic fibrogenesis. Additionally, our review looks into new therapeutic approaches that target HSP70 and HSP47 and could potentially be used as drug candidates to treat liver fibrosis, especially in cases of comorbidities.
Literature
1.
Berumen J, Baglieri J. Liver fibrosis: Pathophysiology and clinical implications. Mech Dis. 2021;13: e1499.
2.
Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37–55.PubMedCrossRef
3.
Abdelhamid AM, Youssef ME, Abd El-Fattah EE, Gobba NA, Gaafar AGA, Girgis S, et al. Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride. Life Sci. 2021;286: 120070.PubMedCrossRef
4.
5.
Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med. 2020;245:96–108.CrossRef
6.
Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci. 2012;109:9448–53.PubMedPubMedCentralCrossRef
7.
Xie G, Diehl AM. Evidence for and against epithelial-to-mesenchymal transition in the liver. Am J Physiol Gastroint Liver Physiol. 2013;305:881–90.CrossRef
8.
Koyama Y, Wang P, Liang S, Iwaisako K, Liu X, Xu J, et al. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J Clin Investig. 2017;127:1254–70.PubMedPubMedCentralCrossRef
9.
El-Ashmawy NE, Salem ML, Abd El-Fattah EE, Khedr EG. Targeting CD166+ lung cancer stem cells: molecular study using murine dendritic cell vaccine. Toxicol Appl Pharmacol. 2021;429: 115699.PubMedCrossRef
10.
Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:S15-24.PubMedCrossRef
11.
12.
13.
Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, Trappoliere M, et al. Adenosine monophosphate–activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology. 2008;47:668–76.PubMedCrossRef
14.
Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.PubMedCrossRef
15.
Pinzani M. Pathophysiology of liver fibrosis. Digestive Dis. 2015;33:492–7.CrossRef
16.
Abd El-Fattah EE, Abdelhamid AM. Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung. Toxicology. 2021;463: 152994.PubMedCrossRef
17.
Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, et al. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed Pharmacother. 2022;145: 112455.PubMedCrossRef
18.
Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et al. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Develo Biol. 2021;9: 730176.CrossRef
19.
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151–66.PubMedCrossRef
20.
21.
22.
Tanguy J, Pommerolle L, Garrido C, Kolb M, Bonniaud P, Goirand F, et al. Extracellular heat shock proteins as therapeutic targets and biomarkers in fibrosing interstitial lung diseases. Intern J Mol Sci. 2021;22:9316.CrossRef
23.
Esmaeili Z, Niaz Q, Saffari PM, Dehpour AR, Rezayat SM, Jazaeri F. Evaluation of the effect of heat shock protein 70 targeted drugs on cirrhotic cardiomyopathy in biliary cirrhotic rats. Life Sci. 2021;273: 119261.PubMedCrossRef
24.
Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, et al. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front Immunol. 2014;5:307.PubMedPubMedCentralCrossRef
25.
26.
Zhao Y, Dang Z, Xu S, Chong S. Heat shock protein 47 effects on hepatic stellate cell-associated receptors in hepatic fibrosis of Schistosoma japonicum-infected mice. Biol Chem. 2017;398:1357–66.PubMedCrossRef
27.
Huang JQ, Tao R, Li L, Ma K, Xu L, Ai G, et al. Involvement of heat shock protein 47 in Schistosoma japonicum-induced hepatic fibrosis in mice. Int J Parasitol. 2014;44:23–35.PubMedCrossRef
28.
Salem ML, El-Ashmawy NE, Abd El-Fattah EE, Khedr EG. Immunosuppressive role of Benzo[a]pyrene in induction of lung cancer in mice. Chem Biol Interact. 2021;333: 109330.PubMedCrossRef
29.
Lønsmann I, Gudmann NS, Manon-Jensen T, Thiele M, Moreno YM, Langholm LL, et al. Serologically assessed heat shock protein 47 is related to fibrosis stage in early compensated alcohol-related liver disease. Clin Biochem. 2022;104:36–43.PubMedCrossRef
30.
Li L, Wu T, Huang J, Ma K, Xu L, Wang H, et al. Expression of heat shock protein 47, transforming growth factor-beta 1, and connective tissue growth factor in liver tissue of patients with Schistosoma japonicum-induced hepatic fibrosis. Parasitology. 2015;142:341–51.PubMedCrossRef
31.
Sato Y, Yoneda A, Shimizu F, Nishimura M, Shimoyama R, Tashiro Y, et al. Resolution of fibrosis by siRNA HSP47 in vitamin a-coupled liposomes induces regeneration of chronically injured livers. J Gastroenterol Hepatol. 2021;36:3418–28.PubMedCrossRef
32.
Huang Y, Lu J, Xu Y, Xiong C, Tong D, Hu N, et al. Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway. Parasit Vectors. 2020;13:254.PubMedPubMedCentralCrossRef
33.
Kurumi H, Takata T, Kanda T, Sugihara T, Kakugawa T, Yokota SI, et al. Investigating the role of heat shock protein 47 in fibrosis in Crohn’s disease. Sci Rep. 2022;12:10966.PubMedPubMedCentralCrossRef
34.
Rizk FH, Sarhan NI, Soliman NA, Ibrahim MAA, Abd-Elsalam M, Abd-Elsalam S. Heat shock protein 47 as indispensible participant in liver fibrosis: Possible protective effect of lactoferrin. IUBMB Life. 2018;70:795–805.PubMedCrossRef
35.
Wei S, Wang Q, Zhou H, Qiu J, Li C, Shi C, et al. miR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression. Molecular Therapy Nucleic Acids. 2019;16:758–69.PubMedPubMedCentralCrossRef
36.
Li L, Zhang L, Zhao X, Cao J, Li J, Chu G. Downregulation of miR-152 contributes to the progression of liver fibrosis via targeting Gli3 in vivo and in vitro. Exp Ther Med. 2019;18:425–34.PubMedPubMedCentral
37.
38.
Zhang K, Han X, Zhang Z, Zheng L, Hu Z, Yao Q, et al. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways. Nat Commun. 2017;8:1–16.
39.
Lin X, Duan X, Liang Y-Y, Su Y, Wrighton KH, Long J, et al. PPM1A functions as a Smad phosphatase to terminate TGFβ signaling. Cell. 2006;125:915–28.PubMedPubMedCentralCrossRef
40.
41.
Hohfeld J, Jentsch S. GrpE-like regulation of the Hsc70 chaperone by the anti-apoptotic protein BAG-1. Embo J. 1998;17:847.CrossRef
42.
Kanelakis KC, Morishima Y, Dittmar KD, Galigniana MD, Takayama S, Reed JC, et al. Differential effects of the hsp70-binding protein BAG-1 on glucocorticoid receptor folding by the hsp90-based chaperone machinery. J Biol Chem. 1999;274:34134–40.PubMedCrossRef
43.
44.
Ishikawa Y, Ito S, Nagata K, Sakai LY, Bächinger HP. Intracellular mechanisms of molecular recognition and sorting for transport of large extracellular matrix molecules. Proc Natl Acad Sci. 2016;113:E6036–44.PubMedPubMedCentralCrossRef
45.
Oecal S, Socher E, Uthoff M, Ernst C, Zaucke F, Sticht H, et al. The pH-dependent client release from the collagen-specific chaperone HSP47 is triggered by a tandem histidine pair. J Biol Chem. 2016;291:12612–26.PubMedPubMedCentralCrossRef
46.
Saga S, Nagata K, Chen W-T, Yamada KM. pH-dependent function, purification, and intracellular location of a major collagen-binding glycoprotein. J Cell Biol. 1987;105:517–27.PubMedCrossRef
47.
Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H. Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives. Mech Ageing Dev. 2021;199: 111572.PubMedCrossRef
48.
Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay H-C, Yang D, et al. Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis. Cell Stem Cell. 2016;18:797–808.PubMedCrossRef
49.
Feng M, Ding J, Wang M, Zhang J, Zhu X, Guan W. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution. Int J Biol Sci. 2018;14:1033.PubMedPubMedCentralCrossRef
50.
Ikenaga N, Peng Z-W, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;66:1697–708.PubMedCrossRef
51.
Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155:1140–53.PubMedCrossRef
52.
Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26:431–42.PubMedCrossRef
53.
Liu H, Chen Z, Jin W, Barve A, Wan Y-JY, Cheng K. Silencing of α-complex protein-2 reverses alcohol-and cytokine-induced fibrogenesis in hepatic stellate cells. Liver Res. 2017;1:70–9.PubMedPubMedCentralCrossRef
54.
Maiers JL, Kostallari E, Mushref M, deAssuncao TM, Li H, Jalan-Sakrikar N, et al. The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice. Hepatology. 2017;65:983–98.PubMedCrossRef
55.
Guo M, Xu W, Yamamoto Y, Suzuki T. Curcumin increases heat shock protein 70 expression via different signaling pathways in intestinal epithelial cells. Arch Biochem Biophys. 2021;707: 108938.PubMedCrossRef
56.
Xia C, Cai Y, Li S, Yang J, Xiao G. Curcumin increases HSP70 expression in primary rat cortical neuronal apoptosis induced by gp120 V3 Loop Peptide. Neurochem Res. 2015;40:1996–2005.PubMedCrossRef
57.
Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr. 2019;73:441–9.PubMedCrossRef
58.
Brunquell J, Morris S, Snyder A, Westerheide SD. Coffee extract and caffeine enhance the heat shock response and promote proteostasis in an HSF-1-dependent manner in Caenorhabditis elegans. Cell Stress Chaperones. 2018;23:65–75.PubMedCrossRef
59.
Liu F, Wang X, Wu G, Chen L, Hu P, Ren H, et al. Coffee consumption decreases risks for hepatic fibrosis and cirrhosis: a meta-analysis. PLoS ONE. 2015;10: e0142457.PubMedPubMedCentralCrossRef
60.
Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51:201–9.PubMedCrossRef
61.
Abd El-Fattah EE, Zakaria AY. Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach. Int Immunopharmacol. 2022;109: 108889.PubMedCrossRef
62.
Sekino N, Kano M, Kobayashi S, Murakami K, Sakata H, Toyozumi T, et al. Metformin-induced heat shock protein family a member 6 is a promising biomarker of esophageal squamous cell carcinoma. Oncology. 2022;100:267–77.PubMedCrossRef
63.
Lee HW, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, et al. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. J Diabetes Complications. 2021;35: 107747.PubMedCrossRef
64.
Copyright © 2022, StatPearls Publishing LLC. 2022.
65.
Sinclair M, Gow PJ, Grossmann M, Shannon A, Hoermann R, Angus PW. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score. Liver Transpl. 2016;22:1482–90.PubMedCrossRef
66.
Salmani S, Razi M, Sarrafzadeh-Rezaei F, Mahmoudian A. Testosterone amplifies HSP70-2a, HSP90 and PCNA expression in experimental varicocele condition: Implication for DNA fragmentation. Reprod Biol. 2020;20:384–95.PubMedCrossRef
67.
Yassin AA, Alwani M, Talib R, Almehmadi Y, Nettleship JE, Alrumaihi K, et al. Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. Aging Male. 2020;23:1553–63.PubMedCrossRef
68.
Ozacmak VH, Barut F, Ozacmak HS. Melatonin provides neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats. J Pineal Res. 2009;47:156–63.PubMedCrossRef
69.
Jie L, Hong R-t, Zhang Y-j, Sha L-l, Chen W, Ren X-f. Melatonin alleviates liver fibrosis by inhibiting autophagy. Current Med Sci. 2022;42:498–504.CrossRef
70.
San-Miguel B, Fernández-Palanca P, Mauriz JL, Tuñón MJ, González-Gallego J. Beneficial effects of melatonin on liver fibrosis: a systematic review of current biological evidence. J Cell Physiol. 2022;237:2740–57.PubMedPubMedCentralCrossRef
71.
Tahan G, Akin H, Aydogan F, Ramadan SS, Yapicier O, Tarcin O, et al. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats. Canad J Surg. 2010;53:313–8.PubMedPubMedCentral
72.
73.
Jiang Y, Rumble JL, Gleixner AM, Unnithan AS, Pulugulla SH, Posimo JM, et al. N-Acetyl cysteine blunts proteotoxicity in a heat shock protein-dependent manner. Neuroscience. 2013;255:19–32.PubMedCrossRef
74.
Pereira-Filho G, Ferreira C, Schwengber A, Marroni C, Zettler C, Marroni N. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. Arq Gastroenterol. 2008;45:156–62.PubMedCrossRef
75.
Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlötzer-Schrehardt U, et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia. 2010;12:550–61.PubMedPubMedCentralCrossRef
76.
Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol. 2012;159:243–6.PubMedPubMedCentralCrossRef
77.
Xu D, Wu Y, Liao Z-X, Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res. 2007;55:280–6.PubMedCrossRef
78.
Zeniya M, Mori T, Yui N, Nomura N, Mandai S, Isobe K, et al. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. Sci Rep. 2017;7:13086.PubMedPubMedCentralCrossRef
79.
Zhao Z, Faden AI, Loane DJ, Lipinski MM, Sabirzhanov B, Stoica BA. Neuroprotective effects of geranylgeranylacetone in experimental traumatic brain injury. J Cerebral Blood Flow Metabol. 2013;33:1897–908.CrossRef
80.
He W, Zhuang Y, Wang L, Qi L, Chen B, Wang M, et al. Geranylgeranylacetone attenuates hepatic fibrosis by increasing the expression of heat shock protein 70. Mol Med Rep. 2015;12:4895–900.PubMedPubMedCentralCrossRef
81.
Senoo T, Sasaki R, Akazawa Y, Ichikawa T, Miuma S, Miyaaki H, et al. Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice. BMC Gastroenterol. 2018;18:34.PubMedPubMedCentralCrossRef
82.
Kim N, Kim JY, Yenari MA. Pharmacological induction of the 70-kDa heat shock protein protects against brain injury. Neuroscience. 2015;284:912–9.PubMedCrossRef
83.
Zhang X, Zhang X, Huang W, Ge X. The role of heat shock proteins in the regulation of fibrotic diseases. Biomed Pharmacother. 2021;135: 111067.PubMedCrossRef
84.
Sugiyama R, Abe M, Nishitsuji H, Murakami Y, Takeuchi H, Takaku H. Induction of heat-shock protein 70 by prostaglandin A1 inhibits HIV-1 Vif-mediated degradation of APOBEC3G. Antiviral Res. 2013;99:307–11.PubMedCrossRef
85.
Gutierrez LLP, Marques CV, Scomazzon SP, Schroeder HT, Fernandes JR, da Silva RJ, et al. A-family anti-inflammatory cyclopentenone prostaglandins: a novel class of non-statin inhibitors of HMG-CoA reductase. Biochimie. 2021;182:37–50.PubMedCrossRef
86.
Abd El-Fattah EE, Saber S, Youssef ME, Eissa H, El-Ahwany E, Amin NA, et al. AKT-AMPKα-mTOR-dependent HIF-1α activation is a new therapeutic target for cancer treatment: a novel approach to repositioning the antidiabetic drug sitagliptin for the management of hepatocellular carcinoma. Front Pharmacol. 2021;12: 720173.PubMedCrossRef
87.
Abdulrahman BA, Abdelaziz D, Thapa S, Lu L, Jain S, Gilch S, et al. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. Sci Rep. 2017;7:17565.PubMedPubMedCentralCrossRef
88.
Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, et al. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. 2016;7:12975–96.PubMedPubMedCentralCrossRef
89.
Carnicelli V, Frascarelli S, Zucchi R. Effect of acute and chronic zofenopril administration on cardiac gene expression. Mol Cell Biochem. 2011;352:301–7.PubMedCrossRef
90.
Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, et al. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle. 2009;8:3960–70.PubMedCrossRef
91.
Han R, Gao B, Sheng R, Zhang LS, Zhang HL, Gu ZL, et al. Synergistic effects of prostaglandin E1 and lithium in a rat model of cerebral ischemia. Acta Pharmacol Sin. 2008;29:1141–9.PubMedCrossRef
92.
El-Ashmawy NE, Al-Ashmawy GM, Fakher HE, Khedr NF. The role of WNT/β-catenin signaling pathway and glutamine metabolism in the pathogenesis of CCl4-induced liver fibrosis: Repositioning of niclosamide and concerns about lithium. Cytokine. 2020;136: 155250.PubMedCrossRef
93.
94.
Ali TFS, Taira N, Iwamaru K, Koga R, Kamo M, Radwan MO, et al. HSP70 induction by bleomycin metal core analogs. Bioorg Med Chem Lett. 2020;30: 127002.PubMedCrossRef
95.
Vásquez-Garzón VR, Ramírez-Cosmes A, Reyes-Jiménez E, Carrasco-Torres G, Hernández-García S, Aguilar-Ruiz SR, et al. Liver damage in bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1503–13.PubMedCrossRef
96.
Wu D, Zhang M, Xu J, Song E, Lv Y, Tang S, et al. In vitro evaluation of aspirin-induced HspB1 against heat stress damage in chicken myocardial cells. Cell Stress Chaperones. 2016;21:405–13.PubMedPubMedCentralCrossRef
97.
Tang S, Zhou S, Yin B, Xu J, Di L, Zhang J, et al. Heat stress-induced renal damage in poultry and the protective effects of HSP60 and HSP47. Cell Stress Chaperones. 2018;23:1033–40.PubMedPubMedCentralCrossRef
98.
Liu Y, Nong L, Jia Y, Tan A, Duan L, Lu Y, et al. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway. Aging. 2020;12:6058–66.PubMedPubMedCentralCrossRef
99.
100.
Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016;43:734–43.PubMedCrossRef
101.
Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, et al. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci. 2008;82:210–7.PubMedCrossRef
102.
Xi Y, Li Y, Xu P, Li S, Liu Z, Tung H-c, et al. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Sci Adv. 2021;7:eabg9241.PubMedPubMedCentralCrossRef
103.
Flores-Contreras L, Sandoval-Rodríguez AS, Mena-Enriquez MG, Lucano-Landeros S, Arellano-Olivera I, Álvarez-Álvarez A, et al. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol. 2014;14:131.PubMedPubMedCentralCrossRef
104.
Wang H, Feng Y, Ming M, Song J, Chen Z, Xiao Z. Amelioration of Cd-induced bioaccumulation, hematological parameters, and heat shock protein-related genes by Vitamin C on common carp. Compar Biochem Physiol Toxicol Pharmacol. 2022;1:109362.CrossRef
105.
Zhao Y, Li H. Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease. Scand J Gastroenterol. 2022;57:872–7.PubMedCrossRef
106.
Hsu Y-C, Chiu Y-T, Lee C-Y, Wu C-F, Huang Y-T. Anti-fibrotic effects of tetrandrine on bile-duct ligated rats. Can J Physiol Pharmacol. 2006;84:967–76.PubMedCrossRef
107.
Park PH, Nan JX, Park EJ, Kang HC, Kim JY, Ko G, et al. Effect of tetrandrine on experimental hepatic fibrosis induced by bile duct ligation and scission in rats. Pharmacol Toxicol. 2000;87:261–8.PubMedCrossRef
108.
Hsu Y-C, Chiu Y-T, Cheng C-C, Wu C-F, Lin Y-L, Huang Y-T. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroenterol Hepatol. 2007;22:99–111.PubMedCrossRef
109.
Yin MF, Lian LH, Piao DM, Nan JX. Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol. 2007;13:1214–20.PubMedPubMedCentralCrossRef
110.
Mostafa TM, El-azab GA, Badra GA, Abdelwahed AS, Elsayed AA. Effect of candesartan and ramipril on liver fibrosis in patients with chronic hepatitis C viral infection: a randomized controlled prospective study. Curr Ther Res. 2021;95: 100654.PubMedPubMedCentralCrossRef
111.
Dafforn TR, Della M, Miller AD. The molecular interactions of heat shock protein 47 (Hsp47) and their implications for collagen biosynthesis. J Biol Chem. 2001;276:49310–9.PubMedCrossRef
112.
El-Alfy M, Deloche C, Azzi L, Bernard B, Bernerd F, Coutet J, et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? Br J Dermatol. 2010;163:968–76.PubMedCrossRef
113.
Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484–92.PubMedCrossRef
114.
Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364:229–33.PubMedCrossRef
115.
Stewart J, Siavash H, Hebert C, Norris K, Nikitakis N, Sauk J. Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells. Oral Oncol. 2003;39:862–9.PubMedCrossRef
116.
Gao B, Sun W, Meng X, Xue D, Zhang W. Screening of differentially expressed protein kinases in bone marrow endothelial cells and the protective effects of the p38a inhibitor SB203580 on bone marrow in liver fibrosis. Mol Med Rep. 2016;14:4629–37.PubMedPubMedCentralCrossRef
117.
Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008;7:829–40.PubMedPubMedCentralCrossRef
118.
Ishida Y, Nagata K. Hsp47 as a collagen-specific molecular chaperone Methods in enzymology. Amsterdam: Elsevier; 2011.
119.
Iwasaki Y-k, Yamashita T, Sekiguchi A, Hayami N, Shimizu W. Importance of pulmonary vein preferential fibrosis for atrial fibrillation promotion in hypertensive rat hearts. Canad J Cardiol. 2016;32:767–76.CrossRef
120.
El-Mezayen NS, El-Hadidy WF, El-Refaie WM, Shalaby TI, Khattab MM, El-Khatib AS. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis. J Control Release. 2017;266:226–37.PubMedCrossRef
121.
Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:G907–13.PubMedCrossRef
122.
Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol. 2006;44:167–75.PubMedCrossRef
123.
Qu K, Huang Z, Lin T, Liu S, Chang H, Yan Z, et al. New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials. Front Pharmacol. 2016;6:300.PubMedPubMedCentralCrossRef
124.
Westra IM, Oosterhuis D, Groothuis GM, Olinga P. The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS ONE. 2014;9: e95462.PubMedPubMedCentralCrossRef
125.
El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Abd El-Fattah EE. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2017;17:185–91.PubMedCrossRef
126.
Yuan S, Wei C, Liu G, Zhang L, Li J, Li L, et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway. Cell Prolif. 2022;55: e13158.PubMedCrossRef
127.
Chen XF, Ji S. Sorafenib attenuates fibrotic hepatic injury through mediating lysine crotonylation. Drug Des Dev Ther. 2022;16:2133–44.CrossRef
128.
Pesce A, Ciurleo R, Bramanti A, Armeli Iapichino EC, Petralia MC, Magro GG, et al. Effects of combined admistration of imatinib and sorafenib in a murine model of liver fibrosis. Molecules. 2020;25(18):4310.PubMedPubMedCentralCrossRef
129.
Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discovery. 2007;6:734–45.PubMedCrossRef
130.
Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007;46:1919–26.PubMedCrossRef
131.
Honma S, Shinohara M, Takahashi N, Nakamura K, Hamano S, Mitazaki S, et al. Effect of cyclooxygenase (COX)-2 inhibition on mouse renal interstitial fibrosis. Eur J Pharmacol. 2014;740:578–83.PubMedCrossRef
132.
Kim SM, Park KC, Kim HG, Han SJ. Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts. Hepatol Res. 2008;38:800–9.PubMedCrossRef
133.
Li L, Song X, Yin Z, Jia R, Li Z, Zhou X, et al. The antibacterial activity and action mechanism of emodin from Polygonum cuspidatum against Haemophilus parasuis in vitro. Microbiol Res. 2016;186:139–45.PubMedCrossRef
134.
Lin W, Wang C, Ling C. Research progress in anti-tumor effect of emodin. Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi. China J Chin Materia Med. 2015;40:3937–40.
135.
Guan R, Zhao X, Wang X, Song N, Guo Y, Yan X, et al. Emodin alleviates bleomycin-induced pulmonary fibrosis in rats. Toxicol Lett. 2016;262:161–72.PubMedCrossRef
136.
Zhao XA, Chen G, Liu Y, Wu H, Chen J, Xiong Y, et al. Emodin alleviates liver fibrosis of mice by reducing infiltration of gr1(hi) monocytes. Evidence Based Complem Alter Med. 2018;2018:5738101.CrossRef
137.
Knüppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol. 2017;57:77–90.PubMedCrossRef
138.
Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:1–9.CrossRef
139.
Staab-Weijnitz CA, Fernandez IE, Knüppel L, Maul J, Heinzelmann K, Juan-Guardela BM, et al. FK506-binding protein 10, a potential novel drug target for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192:455–67.PubMedPubMedCentralCrossRef
140.
141.
Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer. 2003;3:571–81.PubMedCrossRef
142.
Pleasant-Jenkins D, Reese C, Chinnakkannu P, Kasiganesan H, Tourkina E, Hoffman S, et al. Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide. Lab Invest. 2017;97:370–82.PubMedPubMedCentralCrossRef
143.
Liu Y, Liu J, Quimbo A, Xia F, Yao J, Clamme J-P, et al. Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models. ERJ open research 2021;7.
144.
Kuroda K, Tsukifuji R, Shinkai H. Increased expression of heat-shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. J Investig Dermatol. 1998;111:1023–8.PubMedCrossRef
145.
Kakugawa T, Yokota S-i, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaper. 2013;18:581–90.CrossRef
146.
Shimizu H, Shimizu T, Takahashi D, Asano T, Arai R, Takakuwa Y, et al. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report. BMC Musculoskelet Disord. 2019;20:88.PubMedPubMedCentralCrossRef
147.
Westra IM, Mutsaers HA, Luangmonkong T, Hadi M, Oosterhuis D, de Jong KP, et al. Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro. 2016;35:77–85.PubMedCrossRef
Metadata
Title
Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management
Authors
Eslam E. Abd El-Fattah
Amr Y. Zakaria
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03759-z

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Microbiota and metabolites alterations in proximal and distal gastric cancer patients

Research

Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis

Research

Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples

Research

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy

Research

Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy

Research

Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits